

Severity, therapeutic, and activity tear biomarkers in dry eye disease: A clinical-trial sub-analysis

José Pinto-Fraga, Amalia Enríquez-de-Salamanca, Margarita Calonge, María J. González-García, Alberto López-Miguel, Alberto López-de la Rosa, Carmen García-Vázquez, Virginia Calder, Michael E. Stern, Itziar Fernández

PII: S1542-0124(18)30053-3

DOI: [10.1016/j.jtos.2018.05.001](https://doi.org/10.1016/j.jtos.2018.05.001)

Reference: JTOS 299

To appear in: *Ocular Surface*

Received Date: 20 February 2018

Revised Date: 27 April 2018

Accepted Date: 8 May 2018

Please cite this article as: Pinto-Fraga José, Enríquez-de-Salamanca A, Calonge M, González-García MaríJ, López-Miguel A, López-de la Rosa A, García-Vázquez C, Calder V, Stern ME, Fernández I, Severity, therapeutic, and activity tear biomarkers in dry eye disease: A clinical-trial sub-analysis, *Ocular Surface* (2018), doi: 10.1016/j.jtos.2018.05.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Severity, Therapeutic, and Activity Tear Biomarkers in Dry Eye Disease: a clinical-trial sub-analysis

José Pinto-Fraga, PhD¹ Amalia Enríquez-de-Salamanca, PhD^{1,2} Margarita Calonge, MD, PhD^{1,2,3} María J González-García, PhD^{1,2} Alberto López-Miguel, PhD^{1,4} Alberto López-de la Rosa, MSc¹ Carmen García-Vázquez, LT¹ Virginia Calder, PhD⁵ Michael E Stern, PhD,^{3,6} and Itziar Fernández, PhD.^{2,1}

¹IOBA (Institute of Applied OphthalmoBiology), University of Valladolid, Valladolid, Spain.

²CIBER-BBN (Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine), Spain; ³ImmunEyes LLC, USA; ⁴VISION R&D, Valladolid, Spain; ⁵University College London, UCL, London, UK; ⁶Baylor College of Medicine, Houston, TX, USA.

Corresponding author: Amalia Enríquez-de-Salamanca, PhD; Institute of Applied OphthalmoBiology (IOBA), University of Valladolid, Paseo de Belén 17, 47011, Valladolid, Spain. Telephone: +34983186369 Fax: +34983184723. Email: amalia@ioba.med.uva.es

Running Head: Tear inflammatory molecule biomarkers in dry eye disease

Meeting Presentations: These results have been partially presented at ARVO Meeting 2017, May 2017, Baltimore, USA.

Abbreviations and acronyms: ACE=adverse controlled environment; CI=confidence interval; DED=dry eye disease; EGF=epidermal growth factor; FC=fold change; FML=0.1% fluorometholone; HLA-DR=human leukocyte antigen; IFN=interferon; IL=interleukin; IP=Interferon gamma-induced protein; M=moderate; MCP-1=monocyte chemoattractant protein-1; MDS=multidimensional scaling; MIP=macrophage inflammatory protein; MMP=metalloproteinase; NADA=non-detects and data analysis; NCE=normal controlled environment; PA=polyvinyl alcohol; RA=receptor antagonist; RANTES= regulated upon activation, normal T cell expressed and secreted; S=severe; TNF=tumor necrosis factor.

Download English Version:

<https://daneshyari.com/en/article/8591123>

Download Persian Version:

<https://daneshyari.com/article/8591123>

[Daneshyari.com](https://daneshyari.com)